Meeting
2023 ASCO Annual Meeting
A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.
Authors
Itamar Sela
OncoHost LTD, Binyamina, Israel
Itamar Sela , Petros Christopoulos , Igor Puzanov , Jair Bar , Alona Zer , Mor Moskovitz , Niels Reinmuth , Michal Lotem , Rivka Katzenelson , Abed Agbarya , David Farrugia , Gillian Price , Helen Cheley , Mahmud Abu-Amana , Kimberly McGregor , Yanyan Lou , Raya Leibowitz , Adam P. Dicker , David Paul Carbone , David R. Gandara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9122)
DOI
10.1200/JCO.2023.41.16_suppl.9122
Abstract #
9122
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
First Author: Deborah Blythe Doroshow
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
First Author: Maysa Vilbert
Poster
2023 ASCO Quality Care Symposium
Mutation-specific costs of advanced non-small cell lung cancer treatment.
First Author: Juanyi Tan